Table 2.
Association Between Durvalumab Treatment Duration and Progression-Free Survival
| Variable | Univariate |
Multivariatea |
||
|---|---|---|---|---|
| HR (95% CI) | p Value | HR (95% CI) | p Value | |
| Age | 1.01 (0.94–1.08) | 0.763 | — | — |
| Sex | 2.12 (0.62–7.27) | 0.231 | — | — |
| Histologyb | 1.37 (0.36–5.18) | 0.64 | — | — |
| Stage IIIA vs. IIIB/IIIC | 0.27 (0.06–1.26) | 0.094 | 0.14 (003–0.78) | 0.025 |
| Carboplatin vs. cisplatinc | 0.35 (0.08–1.61) | 0.18 | — | — |
| PD-L1 <1% vs. ≥1% | 2.87 (0.79–10.4) | 0.108 | — | — |
| Durvalumab Tx time | 0.63 (0.42–0.95) | 0.028 | 0.52 (0.31–0.88) | 0.014 |
CI, confidence interval; HR, hazard ratio; PD-L1, programmed death-ligand 1; Tx, treatment.
a
Variables with p < 0.1 on univariate analysis were selected for inclusion in multivariate analysis.
b
Adenocarcinoma versus squamous/other.
c
Carboplatin-based versus cisplatin-based chemotherapy regimens.